CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medisun Precision Medicine Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medisun Precision Medicine Ltd
Trust Company Complex, Ajeltake Road
Majuro, MH96960  Marshall Islands
This company is no longer actively traded on any major stock exchange.
Business Summary
Medisun Precision Medicine Ltd. is a development-stage company. The Company is focused on developing neurological therapies to be directly delivered into specific regions of the brain. The Company is developing its ACX-31 program to deliver approximately two chemotherapy drugs, temozolomide in combination with biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) locally to brain tumor sites. Through its second development program, it is developing BranchPoint device that can deliver therapeutics through the radial deployment of a delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. It is based on a neurosurgical delivery platform, which can enable approaches to neurological therapy and be modified for the delivery of a range of therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201712/31/2016YesYes---

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Chief Financial Officer, Director Sophia Y.Sun 35 4/18/2017 4/18/2017
Director WilliamCallahan 56 7/1/2015
Director LishaHuang 57 4/18/2017 4/18/2017
Independent Director Luc H.Meyer 72 9/10/2013 9/10/2013

Business Names
Business Name
ACXA
MPME

General Information
Outstanding Shares: 64,418,954 (As of 8/15/2017)
Stock Exchange: OTC
Federal Tax Id: 460966343


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023